Off label and unlicensed prescribing in a specialist oncology center in Australia

Asia-Pacific Journal of Clinical Oncology

Volumn 5, Issue 4, 2009, Pages 242-246

  Mellor, James D ^a,b,c   Bensted, Karen E ^d   Chan, Pui Lam ^d  

^a Pharmacy Department   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Off label; Oncology; Prescribing; Regulatory; Therapeutic Goods Administration; Unlicensed

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; CYCLIZINE; DEXAMETHASONE; ESOMEPRAZOLE; ETOPOSIDE; FLUCONAZOLE; FLUOROURACIL; FOLINATE CALCIUM; KETAMINE; LORAZEPAM; MACROGOL 3350; METOCLOPRAMIDE; MOUTHWASH; PARACETAMOL; SODIUM CHLORIDE; TRASTUZUMAB; VALACICLOVIR;

ARTICLE; AUSTRALIA; CANCER PATIENT; DRUG MARKETING; HUMAN; LICENSING; MAJOR CLINICAL STUDY; OFF LABEL DRUG USE; ONCOLOGY; PHARMACIST; PRESCRIPTION; PRIORITY JOURNAL; SAFETY; TREATMENT INDICATION;

EID: 71649102622     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2009.01239.x     Document Type: Article

References (15)

1. O'Donnell CPF, Stone RJ, Morley CJ. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics 2002, 110:e52.
2. Poole SG, Dooley MJ. Off-label prescribing in oncology. Support Care Cancer 2004, 12:302-5.
3. Gazarian M, Kelly M, McPhee JR, Graudins LV, Ward RL, Campbell TJ. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust 2006, 185:544-8.
4. Casali PG. The off-label use of drugs in oncology: a position paper by European Society for Medical Oncology (ESMO). Ann Oncol 2007, 18:1923-5.
5. Conroy S, Newman C, Gudka S. Unlicensed and off label drug use in acute lymphoblastic leukaemia and other malignancies in children. Ann Oncol 2003, 14:42-7.
6. Kos M, Wertheimer AI, Mrhar A. Satisfaction with pharmacotherapy for approved and off-label indications - a Delphi study. Ann Pharmacother 2005, 39:649-54.
7. Mortenson LE. The off-label debate: a threat to the future of cancer care. Cancer Invest 1991, 9:597-9.
8. Off-label drugs, reimbursement policies constrain physicians in their choice of cancer therapies. 1991, United States General Accounting Office, report GAO/PEMD-91-14). Washington, DC
9. Atkinson CV, Kirkham SR. Unlicensed uses for medication in a palliative care unit. Palliat Med 1999, 13:145-52.
10. Pavis H, Wilcock A. Prescribing of drugs for use outside their license in palliative care: survey of specialists in the United Kingdom. BMJ 2001, 323:484-5.
11. Todd J, Davies A. Use of unlicensed medication in palliative medicines. Palliat Med 1999, 13:446.
12. Cras A, Conscience MA, Rajzbaum G. Off-label prescribing in a French hospital. Pharm World Sci 2007, 29:97-100.
13. Horen B, Monstastruc JL, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol 2002, 54:665-70.
14. Hill P. Off license and off label prescribing in children: litigation fears of physicians. Arch Dis Child 2005, 90:17-18.
15. Bristol N. Medicare drug expansion causes controversy in the USA. Lancet 2009, 373:532.